You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePaliperidone
Accession NumberDB01267
TypeSmall Molecule
GroupsApproved
DescriptionPaliperidone is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that paliperidone and risperidone act via similar if not the same pathways. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006.
Structure
Thumb
Synonyms
9-Hydroxyrisperidone
Invega
Paliperidone
Ro-76477
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
Invegatablet (extended-release)6 mgoralJanssen Inc2007-10-02Not applicableCanada
Invegatablet, extended release6 mg/1oralJanssen Pharmaceuticals, Inc.2006-12-19Not applicableUs
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
Invegatablet, extended release6 mg/1oralRebel Distributors Corp2006-12-19Not applicableUs
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
Invegatablet, extended release3 mg/1oralTYA Pharmaceuticals2006-12-19Not applicableUs
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
Invegatablet, extended release6 mg/1oralAvera Mc Kennan Hospital2015-05-29Not applicableUs
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
Invegatablet (extended-release)9 mgoralJanssen Inc2007-10-02Not applicableCanada
Invegatablet, extended release9 mg/1oralJanssen Pharmaceuticals, Inc.2006-12-19Not applicableUs
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
Invegatablet, extended release1.5 mg/1oralJanssen Pharmaceuticals, Inc.2009-09-10Not applicableUs
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
Invegatablet (extended-release)12 mgoralJanssen IncNot applicableNot applicableCanada
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
Invegatablet, extended release3 mg/1oralREMEDYREPACK INC.2013-03-272016-04-05Us
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet9 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet3 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet12 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
InvegaProlonged release tablet1.5 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
Invegatablet (extended-release)3 mgoralJanssen Inc2007-10-02Not applicableCanada
Invegatablet, extended release3 mg/1oralJanssen Pharmaceuticals, Inc.2006-12-19Not applicableUs
InvegaProlonged release tablet6 mgOral useJanssen Cilag International Nv2007-06-25Not applicableEu
Invega Sustennasuspension (extended-release)25 mgintramuscularJanssen IncNot applicableNot applicableCanada
Invega Sustennainjection156 mg/mLintramuscularJanssen Pharmaceuticals, Inc.2009-07-31Not applicableUs
Invega Sustennasuspension (extended-release)100 mgintramuscularJanssen Inc2010-07-21Not applicableCanada
Invega Sustennainjection39 mg/.25mLintramuscularJanssen Pharmaceuticals, Inc.2009-07-31Not applicableUs
Invega Sustennainjection234 mg/1.5mLintramuscularJanssen Pharmaceuticals, Inc.2009-07-31Not applicableUs
Invega Sustennasuspension (extended-release)150 mgintramuscularJanssen Inc2010-07-21Not applicableCanada
Invega Sustennasuspension (extended-release)50 mgintramuscularJanssen Inc2010-07-21Not applicableCanada
Invega Sustennainjection78 mg/.5mLintramuscularJanssen Pharmaceuticals, Inc.2009-07-31Not applicableUs
Invega Sustennainjection117 mg/.75mLintramuscularJanssen Pharmaceuticals, Inc.2009-07-31Not applicableUs
Invega Sustennasuspension (extended-release)75 mgintramuscularJanssen Inc2010-07-21Not applicableCanada
Invega Trinzainjection, suspension, extended release410 mg/1.315mLintramuscularJanssen Pharmaceuticals, Inc2015-05-19Not applicableUs
Invega Trinzasuspension (extended-release)263 mgintramuscularJanssen Inc2016-07-25Not applicableCanada
Invega Trinzainjection, suspension, extended release546 mg/1.75mLintramuscularJanssen Pharmaceuticals, Inc2015-05-19Not applicableUs
Invega Trinzasuspension (extended-release)350 mgintramuscularJanssen Inc2016-07-25Not applicableCanada
Invega Trinzainjection, suspension, extended release819 mg/2.625mLintramuscularJanssen Pharmaceuticals, Inc2015-05-19Not applicableUs
Invega Trinzainjection, suspension, extended release273 mg/.875mLintramuscularJanssen Pharmaceuticals, Inc2015-05-19Not applicableUs
Invega Trinzasuspension (extended-release)525 mgintramuscularJanssen Inc2016-07-25Not applicableCanada
Invega Trinzasuspension (extended-release)175 mgintramuscularJanssen Inc2016-07-25Not applicableCanada
Mylan-paliperidonetablet (extended-release)6 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Paliperidonetablet, extended release3 mg/1oralPatriot Pharmaceuticals, LLC2015-09-24Not applicableUs
Paliperidonetablet, extended release1.5 mg/1oralAvera Mc Kennan Hospital2015-09-29Not applicableUs
Paliperidonetablet, extended release6 mg/1oralPatriot Pharmaceuticals, LLC2015-09-24Not applicableUs
Paliperidonetablet, extended release3 mg/1oralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Paliperidonetablet, extended release9 mg/1oralPatriot Pharmaceuticals, LLC2015-09-24Not applicableUs
Paliperidonetablet, extended release1.5 mg/1oralPatriot Pharmaceuticals, LLC2015-09-24Not applicableUs
XeplionProlonged release suspension for injection100 mgIntramuscular useJanssen Cilag International N.V.2011-03-04Not applicableEu
XeplionProlonged release suspension for injection150 mgIntramuscular useJanssen Cilag International N.V.2011-03-04Not applicableEu
XeplionProlonged release suspension for injection25 mgIntramuscular useJanssen Cilag International N.V.2011-03-04Not applicableEu
XeplionProlonged release suspension for injection50 mgIntramuscular useJanssen Cilag International N.V.2011-03-04Not applicableEu
XeplionProlonged release suspension for injection75 mgIntramuscular useJanssen Cilag International N.V.2011-03-04Not applicableEu
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Paliperidonetablet, film coated, extended release9 mg/1oralActavis Pharma, Inc.2015-09-24Not applicableUs
Paliperidonetablet, film coated, extended release1.5 mg/1oralMylan Pharmaceuticals Inc.2015-09-24Not applicableUs
Paliperidonetablet, film coated, extended release1.5 mg/1oralActavis Pharma, Inc.2015-09-24Not applicableUs
Paliperidonetablet, film coated, extended release3 mg/1oralMylan Pharmaceuticals Inc.2015-09-24Not applicableUs
Paliperidonetablet, film coated, extended release3 mg/1oralActavis Pharma, Inc.2015-09-24Not applicableUs
Paliperidonetablet, film coated, extended release6 mg/1oralMylan Pharmaceuticals Inc.2015-09-24Not applicableUs
Paliperidonetablet, film coated, extended release6 mg/1oralActavis Pharma, Inc.2015-09-24Not applicableUs
Paliperidonetablet, film coated, extended release9 mg/1oralMylan Pharmaceuticals Inc.2015-09-24Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Paliperidone palmitate
ThumbNot applicableDBSALT001464
Categories
UNII838F01T721
CAS number144598-75-4
WeightAverage: 426.4839
Monoisotopic: 426.206718955
Chemical FormulaC23H27FN4O3
InChI KeyInChIKey=PMXMIIMHBWHSKN-UHFFFAOYSA-N
InChI
InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3
IUPAC Name
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one
SMILES
CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridopyrimidines. These are compounds containing a pyridopyrimidine, which consists of a pyridine fused to a pyrimidine. Pyridine is 6-membered ring consisting of five carbon atoms and a nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridopyrimidines
Sub ClassNot Available
Direct ParentPyridopyrimidines
Alternative Parents
Substituents
  • Pyridopyrimidine
  • Benzisoxazole
  • Aralkylamine
  • Pyrimidone
  • Fluorobenzene
  • Benzenoid
  • Pyrimidine
  • Pyridine
  • Piperidine
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Oxazole
  • Isoxazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Lactam
  • Oxacycle
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of schizophrenia.
PharmacodynamicsPaliperidone is an atypical antipsychotic developed by Janssen Pharmaceutica. Chemically, paliperidone is primary active metabolite of the older antipsychotic risperidone (paliperidone is 9-hydroxyrisperidone). While its specific mechanism of action is unknown, it is believed paliperidone and risperidone act via similar, if not the same, pathways.
Mechanism of actionPaliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone, as with other drugs having efficacy in schizophrenia, is unknown, but it has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.
Related Articles
AbsorptionThe absolute oral bioavailability of paliperidone following paliperidone administration is 28%.
Volume of distribution
  • 487 L
Protein bindingThe plasma protein binding of racemic paliperidone is 74%.
Metabolism

Although in vitro studies suggested a role for CYP2D6 and CYP3A4 in the metabolism of paliperidone, in vivo results indicate that these isozymes play a limited role in the overall elimination of paliperidone. Four primary metabolic pathways have been identified in vivo, none of which could be shown to account for more than 10% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission. Paliperidone does not undergo extensive metabolism and a significant portion of its metabolism occurs in the kidneys.

Route of eliminationOne week following administration of a single oral dose of 1 mg immediate-release 14C-paliperidone to 5 healthy volunteers, 59% (range 51% – 67%) of the dose was excreted unchanged into urine, 32% (26% – 41%) of the dose was recovered as metabolites, and 6% – 12% of the dose was not recovered.
Half lifeThe terminal elimination half-life of paliperidone is approximately 23 hours.
ClearanceNot Available
ToxicityThe possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7928
Caco-2 permeable-0.5496
P-glycoprotein substrateSubstrate0.7449
P-glycoprotein inhibitor IInhibitor0.7011
P-glycoprotein inhibitor IIInhibitor0.8229
Renal organic cation transporterNon-inhibitor0.6231
CYP450 2C9 substrateNon-substrate0.7721
CYP450 2D6 substrateSubstrate0.5131
CYP450 3A4 substrateSubstrate0.7154
CYP450 1A2 substrateNon-inhibitor0.7379
CYP450 2C9 inhibitorNon-inhibitor0.7395
CYP450 2D6 inhibitorNon-inhibitor0.5326
CYP450 2C19 inhibitorNon-inhibitor0.7815
CYP450 3A4 inhibitorNon-inhibitor0.6468
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7558
Ames testNon AMES toxic0.518
CarcinogenicityNon-carcinogens0.7995
BiodegradationNot ready biodegradable0.9908
Rat acute toxicity3.7859 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8366
hERG inhibition (predictor II)Inhibitor0.7061
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Prolonged release tabletOral use1.5 mg
Prolonged release tabletOral use12 mg
Prolonged release tabletOral use3 mg
Prolonged release tabletOral use6 mg
Prolonged release tabletOral use9 mg
Tablet (extended-release)oral12 mg
Tablet (extended-release)oral3 mg
Tablet (extended-release)oral6 mg
Tablet (extended-release)oral9 mg
Tablet, extended releaseoral3 mg/1
Tablet, extended releaseoral6 mg/1
Injectionintramuscular117 mg/.75mL
Injectionintramuscular156 mg/mL
Injectionintramuscular234 mg/1.5mL
Injectionintramuscular39 mg/.25mL
Injectionintramuscular78 mg/.5mL
Suspension (extended-release)intramuscular100 mg
Suspension (extended-release)intramuscular150 mg
Suspension (extended-release)intramuscular25 mg
Suspension (extended-release)intramuscular50 mg
Suspension (extended-release)intramuscular75 mg
Injection, suspension, extended releaseintramuscular273 mg/.875mL
Injection, suspension, extended releaseintramuscular410 mg/1.315mL
Injection, suspension, extended releaseintramuscular546 mg/1.75mL
Injection, suspension, extended releaseintramuscular819 mg/2.625mL
Suspension (extended-release)intramuscular175 mg
Suspension (extended-release)intramuscular263 mg
Suspension (extended-release)intramuscular350 mg
Suspension (extended-release)intramuscular525 mg
Tablet, extended releaseoral1.5 mg/1
Tablet, extended releaseoral9 mg/1
Tablet, film coated, extended releaseoral1.5 mg/1
Tablet, film coated, extended releaseoral3 mg/1
Tablet, film coated, extended releaseoral6 mg/1
Tablet, film coated, extended releaseoral9 mg/1
Prolonged release suspension for injectionIntramuscular use100 mg
Prolonged release suspension for injectionIntramuscular use150 mg
Prolonged release suspension for injectionIntramuscular use25 mg
Prolonged release suspension for injectionIntramuscular use50 mg
Prolonged release suspension for injectionIntramuscular use75 mg
Prices
Unit descriptionCostUnit
Invega sustenna 39 mg pref syringe296.45USD syringe
Invega er 6 mg tablet28.62USD tablet
Invega er 9 mg tablet23.59USD tablet
Invega er 3 mg tablet23.09USD tablet
Invega er 1.5 mg tablet15.72USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2000786 No1999-01-262009-10-16Canada
CA2494234 No2009-10-272023-07-28Canada
US5254556 No1993-10-272010-10-27Us
US6077843 Yes1997-11-122017-11-12Us
US6555544 Yes1999-05-102019-05-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityPractically insoluble in waterNot Available
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.297 mg/mLALOGPS
logP2.3ALOGPS
logP1.76ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)13.74ChemAxon
pKa (Strongest Basic)8.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area82.17 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity116.04 m3·mol-1ChemAxon
Polarizability45.95 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Santiago Ini, Naama Chasid, Kobi Chen, Osnat Porter-Kleks, “Pure paliperidone and processes for preparing thereof.” U.S. Patent US20080171876, issued July 17, 2008.

US20080171876
General References
  1. Jones MP, Nicholl D, Trakas K: Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. Int J Clin Pharmacol Ther. 2010 Jun;48(6):383-99. [PubMed:20497747 ]
  2. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
External Links
ATC CodesN05AX13
AHFS Codes
  • 28:16.08.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetaminePaliperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetaminePaliperidone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Paliperidone is combined with 7-Nitroindazole.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Paliperidone.
AcebutololPaliperidone may increase the atrioventricular blocking (AV block) activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Aceprometazine.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Paliperidone.
adipiplonThe risk or severity of adverse effects can be increased when Paliperidone is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Agomelatine.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Paliperidone.
AlfaxaloneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Paliperidone.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Paliperidone.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Paliperidone.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Paliperidone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Paliperidone.
AlprenololPaliperidone may increase the atrioventricular blocking (AV block) activities of Alprenolol.
AmantadineAmantadine may increase the QTc-prolonging activities of Paliperidone.
AmineptineThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Amineptine.
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Paliperidone.
AmisulprideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amisulpride.
AmitriptylineThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amperozide.
AmphetaminePaliperidone may decrease the stimulatory activities of Amphetamine.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Paliperidone.
ApomorphineApomorphine may increase the QTc-prolonging activities of Paliperidone.
ArformoterolArformoterol may increase the QTc-prolonging activities of Paliperidone.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Paliperidone.
ArotinololPaliperidone may increase the atrioventricular blocking (AV block) activities of Arotinolol.
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Paliperidone.
ArtemetherPaliperidone may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Articaine.
AsenapinePaliperidone may increase the QTc-prolonging activities of Asenapine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Paliperidone.
AtenololPaliperidone may increase the atrioventricular blocking (AV block) activities of Atenolol.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Paliperidone.
AzaperoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Azaperone.
AzelastinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Paliperidone.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Paliperidone.
BaclofenThe risk or severity of adverse effects can be increased when Paliperidone is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Barbital.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Paliperidone.
BefunololPaliperidone may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Paliperidone.
BenzphetaminePaliperidone may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Paliperidone is combined with Benzyl alcohol.
BetaxololPaliperidone may increase the atrioventricular blocking (AV block) activities of Betaxolol.
BevantololPaliperidone may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BisoprololPaliperidone may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
BopindololPaliperidone may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BortezomibBortezomib may increase the QTc-prolonging activities of Paliperidone.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
BrimonidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Paliperidone.
BrompheniramineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brotizolam.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Paliperidone.
BufuralolPaliperidone may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Paliperidone.
BupranololPaliperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Paliperidone.
BuserelinBuserelin may increase the QTc-prolonging activities of Paliperidone.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Paliperidone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Paliperidone.
ButacaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Paliperidone.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Paliperidone.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Paliperidone.
CarbamazepineThe serum concentration of Paliperidone can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carisoprodol.
CarteololPaliperidone may increase the atrioventricular blocking (AV block) activities of Carteolol.
CarvedilolPaliperidone may increase the atrioventricular blocking (AV block) activities of Carvedilol.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Paliperidone.
CeliprololPaliperidone may increase the atrioventricular blocking (AV block) activities of Celiprolol.
CeritinibCeritinib may increase the QTc-prolonging activities of Paliperidone.
CetirizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paliperidone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Paliperidone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Paliperidone.
ChloroquineChloroquine may increase the QTc-prolonging activities of Paliperidone.
ChlorphenamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chlorphenamine.
ChlorphenterminePaliperidone may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Paliperidone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Paliperidone.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Paliperidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chlorzoxazone.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Paliperidone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Paliperidone.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Paliperidone.
CisaprideCisapride may increase the QTc-prolonging activities of Paliperidone.
CitalopramCitalopram may increase the QTc-prolonging activities of Paliperidone.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Paliperidone.
ClemastineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Paliperidone is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clomipramine.
ClomipramineThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paliperidone.
ClozapineClozapine may increase the QTc-prolonging activities of Paliperidone.
ClozapineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clozapine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Paliperidone.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Paliperidone.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Paliperidone.
CyclizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cyclizine.
CyclobenzaprineThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Cyclobenzaprine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cyclobenzaprine.
CyproheptadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cyproheptadine.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Paliperidone.
DantroleneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Paliperidone.
DapoxetineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dapoxetine.
DasatinibDasatinib may increase the QTc-prolonging activities of Paliperidone.
DegarelixDegarelix may increase the QTc-prolonging activities of Paliperidone.
deramciclaneThe risk or severity of adverse effects can be increased when Paliperidone is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Paliperidone.
DesipramineThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Paliperidone.
DetomidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Paliperidone.
DextroamphetaminePaliperidone may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Paliperidone.
DextromoramideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Paliperidone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Paliperidone.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Paliperidone.
DifenoxinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Paliperidone.
DihydroetorphineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Paliperidone.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Paliperidone.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Paliperidone.
DofetilideDofetilide may increase the QTc-prolonging activities of Paliperidone.
DolasetronDolasetron may increase the QTc-prolonging activities of Paliperidone.
DomperidoneDomperidone may increase the QTc-prolonging activities of Paliperidone.
DoramectinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Doramectin.
DosulepinThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Dosulepin.
DoxepinThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
DoxylamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Paliperidone is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
DronedaronePaliperidone may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Paliperidone.
DroperidolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Drotebanol.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Paliperidone.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Paliperidone.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Paliperidone.
EcgonineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Paliperidone is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Paliperidone is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Paliperidone.
EliglustatPaliperidone may increase the QTc-prolonging activities of Eliglustat.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Paliperidone.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Paliperidone.
EntacaponeThe risk or severity of adverse effects can be increased when Paliperidone is combined with Entacapone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paliperidone.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Paliperidone.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Paliperidone.
EribulinEribulin may increase the QTc-prolonging activities of Paliperidone.
ErythromycinErythromycin may increase the QTc-prolonging activities of Paliperidone.
EscitalopramEscitalopram may increase the QTc-prolonging activities of Paliperidone.
EsmirtazapineThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Esmirtazapine.
EsmololPaliperidone may increase the atrioventricular blocking (AV block) activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Paliperidone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Paliperidone.
EthanolPaliperidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Paliperidone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paliperidone.
EthosuximideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Paliperidone.
EtoperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etorphine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Paliperidone.
EzogabineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Paliperidone.
FelbamateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Paliperidone.
FexofenadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fexofenadine.
FingolimodFingolimod may increase the QTc-prolonging activities of Paliperidone.
FlecainideFlecainide may increase the QTc-prolonging activities of Paliperidone.
FlibanserinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flibanserin.
FluconazoleFluconazole may increase the QTc-prolonging activities of Paliperidone.
FludiazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flunitrazepam.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Paliperidone.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Paliperidone.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Paliperidone.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Paliperidone.
FluspirileneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Paliperidone.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Paliperidone.
FosphenytoinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Paliperidone.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Paliperidone.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Paliperidone is combined with gabapentin enacarbil.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Paliperidone.
GalantamineGalantamine may increase the QTc-prolonging activities of Paliperidone.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Paliperidone is combined with Gamma Hydroxybutyric Acid.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Paliperidone.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Paliperidone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Paliperidone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Paliperidone.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Paliperidone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Paliperidone.
GlutethimideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Glutethimide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Paliperidone.
GoserelinGoserelin may increase the QTc-prolonging activities of Paliperidone.
GranisetronGranisetron may increase the QTc-prolonging activities of Paliperidone.
GuanfacineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Paliperidone.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Paliperidone.
HaloperidolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Paliperidone.
HeroinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Paliperidone is combined with Hexobarbital.
HistrelinHistrelin may increase the QTc-prolonging activities of Paliperidone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Paliperidone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Paliperidone.
Hydroxyamphetamine hydrobromidePaliperidone may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
HydroxyzineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Paliperidone.
IbutilideIbutilide may increase the QTc-prolonging activities of Paliperidone.
IloperidonePaliperidone may increase the QTc-prolonging activities of Iloperidone.
ImipramineThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Imipramine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Paliperidone.
IndalpineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Indalpine.
IndapamideIndapamide may increase the QTc-prolonging activities of Paliperidone.
IndenololPaliperidone may increase the atrioventricular blocking (AV block) activities of Indenolol.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Paliperidone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Paliperidone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Paliperidone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Paliperidone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Paliperidone.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Paliperidone.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Paliperidone.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Paliperidone.
IsradipineIsradipine may increase the QTc-prolonging activities of Paliperidone.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Paliperidone.
IvabradineIvabradine may increase the QTc-prolonging activities of Paliperidone.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Paliperidone.
KetazolamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ketobemidone.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Paliperidone.
LabetalolPaliperidone may increase the atrioventricular blocking (AV block) activities of Labetalol.
LamotrigineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lamotrigine.
LapatinibLapatinib may increase the QTc-prolonging activities of Paliperidone.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Paliperidone.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Paliperidone.
LevetiracetamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Paliperidone.
LevocabastineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levodopa.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Paliperidone.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Paliperidone.
LevomilnacipranThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Paliperidone.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Paliperidone.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Paliperidone.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Paliperidone.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Paliperidone.
LisdexamfetaminePaliperidone may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Paliperidone.
LithiumThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lofentanil.
LopinavirPaliperidone may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Paliperidone.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Paliperidone.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Paliperidone.
Lu AA21004The risk or severity of adverse effects can be increased when Paliperidone is combined with Lu AA21004.
LumefantrinePaliperidone may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Paliperidone.
MeclizineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Medetomidine.
MefloquineMefloquine may increase the QTc-prolonging activities of Paliperidone.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Paliperidone.
MelperoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Melperone.
MephenterminePaliperidone may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Paliperidone.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paliperidone.
MequitazinePaliperidone may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Paliperidone.
MetaxaloneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Metaxalone.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone.
MethadoneMethadone may increase the QTc-prolonging activities of Paliperidone.
MethadoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methadyl Acetate.
MethamphetaminePaliperidone may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Paliperidone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Paliperidone.
MethsuximideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Paliperidone.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paliperidone.
MetoprololPaliperidone may increase the atrioventricular blocking (AV block) activities of Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Paliperidone.
MetyrosinePaliperidone may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Paliperidone.
MianserinThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Mianserin.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Paliperidone.
MifepristoneMifepristone may increase the QTc-prolonging activities of Paliperidone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Paliperidone.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Paliperidone.
MilnacipranThe risk or severity of adverse effects can be increased when Paliperidone is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
MirabegronMirabegron may increase the QTc-prolonging activities of Paliperidone.
MirtazapinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Mirtazapine.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Paliperidone.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Paliperidone.
MoexiprilMoexipril may increase the QTc-prolonging activities of Paliperidone.
MolindoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Paliperidone.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Paliperidone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.
NabiloneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Nabilone.
NadololPaliperidone may increase the atrioventricular blocking (AV block) activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Paliperidone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Paliperidone.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Paliperidone.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Paliperidone.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Paliperidone.
NicardipineNicardipine may increase the QTc-prolonging activities of Paliperidone.
NilotinibPaliperidone may increase the QTc-prolonging activities of Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Nitrous oxide.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Paliperidone.
NormethadoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Normethadone.
NortriptylineThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Nortriptyline.
OctreotideOctreotide may increase the QTc-prolonging activities of Paliperidone.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Paliperidone.
OlanzapineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Olanzapine.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Paliperidone.
OlopatadineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Olopatadine.
OndansetronOndansetron may increase the QTc-prolonging activities of Paliperidone.
OndansetronThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Paliperidone is combined with Opium.
OrphenadrinePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Paliperidone.
OsanetantThe risk or severity of adverse effects can be increased when Paliperidone is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Paliperidone.
OxprenololThe risk or severity of adverse effects can be increased when Paliperidone is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Paliperidone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Paliperidone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Paliperidone.
OxytocinOxytocin may increase the QTc-prolonging activities of Paliperidone.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Paliperidone.
ParaldehydePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Paliperidone.
ParoxetineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Paliperidone.
PazopanibPazopanib may increase the QTc-prolonging activities of Paliperidone.
PenbutololPaliperidone may increase the atrioventricular blocking (AV block) activities of Penbutolol.
PentamidinePentamidine may increase the QTc-prolonging activities of Paliperidone.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Paliperidone.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Paliperidone.
PerampanelThe risk or severity of adverse effects can be increased when Paliperidone is combined with Perampanel.
PerflutrenPerflutren may increase the QTc-prolonging activities of Paliperidone.
PerospironeThe risk or severity of adverse effects can be increased when Paliperidone is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Paliperidone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Paliperidone.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Paliperidone.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Paliperidone.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Paliperidone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Phenoxyethanol.
PhenterminePaliperidone may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Phenytoin.
PimozidePimozide may increase the QTc-prolonging activities of Paliperidone.
PindololPaliperidone may increase the atrioventricular blocking (AV block) activities of Pindolol.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Paliperidone.
PipamperoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pomalidomide.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Paliperidone.
PractololPaliperidone may increase the atrioventricular blocking (AV block) activities of Practolol.
PramipexolePaliperidone may increase the sedative activities of Pramipexole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Paliperidone.
PramocaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Paliperidone.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Paliperidone.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Paliperidone.
PrimidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Primidone.
ProcainamideProcainamide may increase the QTc-prolonging activities of Paliperidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Paliperidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Paliperidone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paliperidone.
PromazinePromazine may increase the QTc-prolonging activities of Paliperidone.
PromazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Paliperidone.
PropafenonePropafenone may increase the QTc-prolonging activities of Paliperidone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Paliperidone.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Paliperidone.
PropoxycaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Propoxycaine.
PropranololPaliperidone may increase the atrioventricular blocking (AV block) activities of Propranolol.
ProtriptylineThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Paliperidone is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Quazepam.
QuetiapineQuetiapine may increase the QTc-prolonging activities of Paliperidone.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Paliperidone.
QuinidineQuinidine may increase the QTc-prolonging activities of Paliperidone.
QuinineQuinine may increase the QTc-prolonging activities of Paliperidone.
RamelteonThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ramelteon.
RanolazineRanolazine may increase the QTc-prolonging activities of Paliperidone.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Paliperidone.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Paliperidone.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Paliperidone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Paliperidone.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Paliperidone.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Paliperidone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Paliperidone.
RitonavirRitonavir may increase the QTc-prolonging activities of Paliperidone.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Paliperidone.
RomifidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Romifidine.
RopinirolePaliperidone may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Paliperidone.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Paliperidone.
RotigotinePaliperidone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Paliperidone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Paliperidone is combined with S-Ethylisothiourea.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Paliperidone.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Paliperidone.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Paliperidone.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Paliperidone.
ScopolamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paliperidone.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Paliperidone.
SertindoleThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Paliperidone.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Paliperidone.
Sodium oxybateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sodium oxybate.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Paliperidone.
SorafenibSorafenib may increase the QTc-prolonging activities of Paliperidone.
SotalolSotalol may increase the QTc-prolonging activities of Paliperidone.
St. John's WortThe serum concentration of Paliperidone can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Paliperidone is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Paliperidone.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Paliperidone.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Paliperidone.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Paliperidone.
SulpirideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Paliperidone.
SunitinibSunitinib may increase the QTc-prolonging activities of Paliperidone.
SuvorexantThe risk or severity of adverse effects can be increased when Paliperidone is combined with Suvorexant.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Paliperidone.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Paliperidone.
TasimelteonThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Paliperidone.
TelavancinTelavancin may increase the QTc-prolonging activities of Paliperidone.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Paliperidone.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Paliperidone.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Paliperidone.
TetrabenazinePaliperidone may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tetrodotoxin.
ThalidomidePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Paliperidone.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Paliperidone.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Paliperidone.
ThioridazineThioridazine may increase the QTc-prolonging activities of Paliperidone.
ThiothixeneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tiagabine.
TianeptineThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Tianeptine.
TiletamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tiletamine.
TimololPaliperidone may increase the atrioventricular blocking (AV block) activities of Timolol.
TizanidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tizanidine.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Paliperidone.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Paliperidone.
TolcaponeThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tolcapone.
TolterodineTolterodine may increase the QTc-prolonging activities of Paliperidone.
TopiramateThe risk or severity of adverse effects can be increased when Paliperidone is combined with Topiramate.
ToremifeneToremifene may increase the QTc-prolonging activities of Paliperidone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Paliperidone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Paliperidone.
TrazodoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Paliperidone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Paliperidone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paliperidone.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Paliperidone.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Paliperidone.
TrimipramineThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Triprolidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Paliperidone.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Paliperidone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Paliperidone.
VandetanibPaliperidone may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Paliperidone.
VemurafenibPaliperidone may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Paliperidone.
VigabatrinThe risk or severity of adverse effects can be increased when Paliperidone is combined with Vigabatrin.
VilanterolVilanterol may increase the QTc-prolonging activities of Paliperidone.
VilazodoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Vilazodone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Paliperidone.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Paliperidone.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Paliperidone.
VorinostatVorinostat may increase the QTc-prolonging activities of Paliperidone.
VortioxetineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Paliperidone.
ZiconotideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zimelidine.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Paliperidone.
ZolazepamThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Paliperidone.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Paliperidone.
ZonisamideThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Paliperidone.
ZotepineThe risk or severity of adverse effects can be increased when Paliperidone is combined with Zotepine.
ZuclopenthixolPaliperidone may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043 ]
  2. He H, Richardson JS: A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol. 1995 Mar;10(1):19-30. [PubMed:7542676 ]
  3. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  4. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
  5. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  6. Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, Tsuchiya F, Sawada Y, Iga T: Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy. Synapse. 2002 Oct;46(1):32-7. [PubMed:12211096 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043 ]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
  3. Regenthal R, Kunstler U, Hesse S, Sabri O, Preiss R: D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients. Int J Clin Pharmacol Ther. 2005 Aug;43(8):370-8. [PubMed:16119512 ]
  4. Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S: A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006 Mar;163(3):396-401. [PubMed:16513859 ]
  5. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  6. Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, Tsuchiya F, Sawada Y, Iga T: Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy. Synapse. 2002 Oct;46(1):32-7. [PubMed:12211096 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043 ]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043 ]
  2. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876 ]
  3. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  4. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090 ]
  5. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
  6. Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J, Mulvany MJ: Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychopharmacology (Berl). 2008 Jul;199(1):15-27. doi: 10.1007/s00213-007-1064-9. Epub 2008 Jun 10. [PubMed:18542932 ]
  7. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  8. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Cohen LJ: Risperidone. Pharmacotherapy. 1994 May-Jun;14(3):253-65. [PubMed:7524043 ]
  2. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876 ]
  3. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  4. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090 ]
  5. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
  6. Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J, Mulvany MJ: Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychopharmacology (Berl). 2008 Jul;199(1):15-27. doi: 10.1007/s00213-007-1064-9. Epub 2008 Jun 10. [PubMed:18542932 ]
  7. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  8. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Gunes A, Spina E, Dahl ML, Scordo MG: ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit. 2008 Oct;30(5):628-33. doi: 10.1097/FTD.0b013e3181858ca9. [PubMed:18708991 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Boerth JM, Caley CF, Goethe JW: Interpreting serum risperidone concentrations. Pharmacotherapy. 2005 Feb;25(2):299-302. [PubMed:15767244 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Yasui-Furukori N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G: Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8. [PubMed:11560868 ]
Comments
comments powered by Disqus
Drug created on May 16, 2007 14:09 / Updated on September 24, 2016 03:31